Point72 Asia Singapore Pte. Ltd. Purchases New Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 9,857 shares of the biopharmaceutical company’s stock, valued at approximately $153,000.

A number of other hedge funds have also made changes to their positions in CPRX. GAMMA Investing LLC increased its position in shares of Catalyst Pharmaceuticals by 72.9% during the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares in the last quarter. CWM LLC boosted its stake in Catalyst Pharmaceuticals by 686.5% during the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter worth $70,000. Headlands Technologies LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the first quarter worth $154,000. Finally, XTX Topco Ltd raised its position in shares of Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 773 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Truist Financial upped their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, August 9th. HC Wainwright lifted their price objective on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Oppenheimer restated an “outperform” rating and issued a $29.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, June 6th. Finally, Citigroup lifted their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $29.50.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $19.56 on Friday. The firm has a 50-day simple moving average of $19.22 and a two-hundred day simple moving average of $16.95. Catalyst Pharmaceuticals, Inc. has a 1-year low of $11.55 and a 1-year high of $21.67. The stock has a market cap of $2.31 billion, a PE ratio of 36.22, a P/E/G ratio of 3.27 and a beta of 0.75.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The company had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. As a group, sell-side analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Insider Activity

In related news, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the transaction, the director now directly owns 348,874 shares in the company, valued at approximately $7,012,367.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Steve Miller sold 150,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the transaction, the insider now owns 675,124 shares in the company, valued at $13,738,773.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 201,058 shares of company stock valued at $4,018,188. 11.00% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.